Related Experiment Videos
[Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study]
Abstract:
In the past decade, the use of a large variety of cellular models and cell biology, biochemistry and molecular biology techniques has led to the discovery of key proteins that are intimately involved in the regulation of tumor growth. In particular, it has been shown that cyclin-dependent kinases (CDKs) are key regulators of the cell-division cycle. Their frequent deregulation in human tumors make them attractive targets for the identification of new antineoplasic agents. Intensive screening has led in the past few years to the identification of a series of selective and potent chemical inhibitors of CDKs. Drugs representing new lead structures like flavopiridol, indirubin and staurosporine++ derivatives have already been used in clinical evaluation for cancer treatment (clinical trials, phase I and II). Anticancer drug development is being pursued to reduce their toxic side effects, to improve their pharmacokinetic properties and to increase their anti-tumor activity. In this context, traditional drug screening methods in biological test systems have led to the discovery of new compounds such as purine derivatives and paullones, which display remarkable selectivity and efficiency. These novels drugs may result in substantial progress in cancer treatment in the near future.
Insights
Researchers are developing novel anticancer drugs targeting cyclin-dependent kinases (CDKs), key regulators of cell division frequently altered in tumors. New CDK inhibitors show promise for more effective cancer treatments with fewer side effects.
Area of Science:
- Molecular Biology
- Biochemistry
- Cell Biology
- Oncology
Context:
- Cyclin-dependent kinases (CDKs) are critical regulators of the cell-division cycle.
- Deregulation of CDKs is common in human tumors, making them significant therapeutic targets.
- Advances in cellular models and molecular techniques have identified key proteins in tumor growth regulation.
Purpose:
- To identify and develop novel antineoplastic agents targeting CDK pathways.
- To discover selective and potent chemical inhibitors of CDKs for cancer treatment.
- To improve the efficacy and reduce the toxicity of existing and novel anticancer drugs.
Summary:
- Intensive screening has identified selective CDK inhibitors, including flavopiridol, indirubin, and staurosporine derivatives.
- New compounds like purine derivatives and paullones exhibit remarkable selectivity and efficiency.
- Several novel CDK inhibitors are undergoing clinical evaluation (Phase I and II trials) for cancer therapy.
Impact:
- Development of targeted anticancer therapies with improved pharmacokinetic properties and reduced side effects.
- Potential for significant progress in cancer treatment through novel drug discovery and development.
- Enhanced anti-tumor activity of new chemical entities targeting cell-division cycle regulators.